JP2015505535A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505535A5
JP2015505535A5 JP2014553448A JP2014553448A JP2015505535A5 JP 2015505535 A5 JP2015505535 A5 JP 2015505535A5 JP 2014553448 A JP2014553448 A JP 2014553448A JP 2014553448 A JP2014553448 A JP 2014553448A JP 2015505535 A5 JP2015505535 A5 JP 2015505535A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
e4orf1
adenovirus
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553448A
Other languages
English (en)
Japanese (ja)
Other versions
JP6175076B2 (ja
JP2015505535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/022126 external-priority patent/WO2013109876A1/en
Publication of JP2015505535A publication Critical patent/JP2015505535A/ja
Publication of JP2015505535A5 publication Critical patent/JP2015505535A5/ja
Application granted granted Critical
Publication of JP6175076B2 publication Critical patent/JP6175076B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553448A 2012-01-20 2013-01-18 Ａｄ３６ｅ４ｏｒｆ１およびａｋｔ１阻害剤を使用した血糖コントロールの向上 Expired - Fee Related JP6175076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588959P 2012-01-20 2012-01-20
US61/588,959 2012-01-20
PCT/US2013/022126 WO2013109876A1 (en) 2012-01-20 2013-01-18 Enhanced glycemic control using ad36e4orf1 and akt1 inhibitor

Publications (3)

Publication Number Publication Date
JP2015505535A JP2015505535A (ja) 2015-02-23
JP2015505535A5 true JP2015505535A5 (enExample) 2016-02-25
JP6175076B2 JP6175076B2 (ja) 2017-08-02

Family

ID=47664431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553448A Expired - Fee Related JP6175076B2 (ja) 2012-01-20 2013-01-18 Ａｄ３６ｅ４ｏｒｆ１およびａｋｔ１阻害剤を使用した血糖コントロールの向上

Country Status (7)

Country Link
US (1) US9433659B2 (enExample)
EP (1) EP2804616B1 (enExample)
JP (1) JP6175076B2 (enExample)
AU (1) AU2013209580B2 (enExample)
BR (1) BR112014017683A2 (enExample)
CA (1) CA2865202A1 (enExample)
WO (1) WO2013109876A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080777A1 (en) * 2023-10-10 2025-04-17 Texas Tech University System Ad36e4orf1 peptide fragments as anti-diabetic agents
WO2025264791A1 (en) * 2024-06-18 2025-12-26 Texas Tech University System Recruiting the contribution of dlg1 to enhance insulin signaling pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632013C (en) * 2005-11-30 2013-02-26 Wayne State University Adenovirus 36 e4 orf 1 gene and protein and their uses
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Similar Documents

Publication Publication Date Title
Lundstrom Viral vectors in gene therapy: where do we stand in 2023?
Vázquez-Domínguez et al. Molecular therapies for inherited retinal diseases—current standing, opportunities and challenges
Haller et al. Mx GTPases: dynamin-like antiviral machines of innate immunity
EP3049116B1 (en) Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
Theis et al. Lentiviral delivery of miR-133b improves functional recovery after spinal cord injury in mice
Song et al. Evidence for an RNA chaperone function of polypyrimidine tract-binding protein in picornavirus translation
Van Gestel et al. shRNA-induced saturation of the microRNA pathway in the rat brain
JP2014504150A5 (enExample)
Dickinson et al. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2017538401A5 (enExample)
JP2016500513A5 (enExample)
JP2019523648A5 (enExample)
JP2013521789A5 (enExample)
JP2015513897A5 (enExample)
JP2008056679A5 (enExample)
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
JP2018528237A5 (enExample)
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
IN2012DN02981A (enExample)
JP2014526881A5 (enExample)
JP2015522264A5 (enExample)
Tan et al. mRNA vaccine-A new cancer treatment strategy
Zinzula et al. dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35
Zhuo et al. piSTING: A Pocket‐Independent Agonist Based on Multivalency‐Driven STING Oligomerization